Navigation Links
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Date:6/9/2009

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD).

The EMEA agreed that should the new confirmatory Phase 3 study produce positive results, the data would be sufficient to support a marketing authorization approval in all 27 European Union (EU) member states. In so doing, the EMEA agreed to the primary endpoint and the other principal design features of the new study. The EMEA's response is consistent with feedback previously received from United States Food and Drug Administration (FDA), paving the way for potential approval in the US and EU.

DOR and the FDA reached agreement on the design of the upcoming Phase 3 study via the Special Protocol Assessment (SPA) procedure. An agreement via the SPA procedure is an agreement with the FDA that a Phase 3 clinical trial's design (e.g., endpoints, sample size, control group and statistical analyses) is acceptable to support a regulatory submission seeking new drug approval.

Based on data from the prior Phase 3 study of orBec(R), the upcoming confirmatory Phase 3 clinical trial will be a highly powered, double-blind, randomized, placebo-controlled, multicenter trial and will seek to enroll an estimated 166 patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value = 0.005) in the previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec(R) (i.e., 30 days following cessation of treatment). The confirmatory Phase 3 clinical trial wi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
4. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
7. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Texas , March 2, 2015 /PRNewswire/ ... of the population with nearly 38,000 of ... (Methicillin-resistant Staphylococcus Aureus), a highly contagious disease, ... 19,000 deaths.  Each of these and more, ... transmitted through casual contact with other infectious ...
(Date:3/2/2015)... Calif. , March 2, 2015  CytomX, ... treatment of cancer, today announced the creation of ... researchers and clinicians in the fields of cancer ... The new advisory boards will provide guidance to ... pipeline of precision immunotherapies and Probody drug conjugates. ...
(Date:3/2/2015)... DIEGO , March 2, 2015   ... clinical-stage biopharmaceutical company, today announced preliminary findings from ... in a model of chronic, stable heart failure ... this study was to examine the effects of ... (LV) systolic and diastolic function. ...
Breaking Medicine Technology:Cleanint Rolls Out Cleanstethoscope and Cleanhands to Largest Medical Transportation Company in the Nation 2Cleanint Rolls Out Cleanstethoscope and Cleanhands to Largest Medical Transportation Company in the Nation 3CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6
... BEACH, Fla., Jan. 26, 2012 China Nuvo Solar ... name change to SurgLine International, Inc. has been completed ... under the new OTC ticker symbol: SGLN, effective tomorrow, ... owned operating subsidiary of SGLN. Thomas Toland, ...
... diversion and the health consequences of prescription drug misuse ... physicians," states American Society of Addiction Medicine (ASAM) Acting ... are overdosing on prescription pain medication and many of ... Chronic pain and addiction are issues faced by ...
Cached Medicine Technology:China Nuvo Solar Energy, Inc. Completes Name Change to SurgLine International, Inc. 2ASAM Approves Prescription Drug Policy 2
(Date:3/2/2015)... “ Wants and Needs ” was featured ... features the latest and coolest mobile applications on the ... technology expert and host of NewsWatch, conducted the app ... people evaluate priorities. , Whether a person needs help ... app. The app allows people to enter and track ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Gummy smile ... reshaping procedures. Gum reshaping can involve one or several procedures ... regenerate lost gum tissue for a more even gum line. ... gum line treatment that can permanently lighten discolored or ... smile approach, which involves a personalized treatment plan to address ...
(Date:3/2/2015)... 02, 2015 The Workgroup for Electronic ... the use of health IT to create efficiencies in ... Testing for Small Providers.” The white paper by WEDI’s ... point for ICD-10 testing by focusing on primary considerations ... compliance with the October 1, 2015 implementation date. Download ...
(Date:3/2/2015)... PORTLAND, Oregon (PRWEB) March 02, 2015 ... world’s largest online healthcare certification programs, including ... compliance, and dietary supplement safety and classification, ... sellers of prescription eyeglasses. The new program, ... eyeglasses prescription verification, transparency regarding the identity ...
(Date:3/2/2015)... A true renaissance man—some might call him ... cult rock band Khazad Doom, has long inspired his countless ... despite all odds. His motto throughout his life has always ... goal was before him. And that attitude, born amidst the ... on to a new generation. , As Eadon knows, when ...
Breaking Medicine News(10 mins):Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3
... whether to preserve the Roman Catholic Church's "traditional ban ... that gives us an effective weapon against AIDS -- ... infallibility to new challenges," according to Peter Boulay, former ... ,Cardinal Javier Lozano Barragan in April said that ...
... Hong Kong health director Margaret Chan Tuesday emerged as ... Health Organisation (WHO). // ,The 60-year-old obstetrician, who ... a five-person shortlist of candidates released overnight ahead of ... ,Chan got 32 votes in the first round of ...
... in delayed healing in mice. It is quite shocking ... having harmful effects on variety of orthopedic conditions are ... that the toxins contained in cigarette can undermine fracture ... are highly prone to hip fractures, healing problems, bone ...
... or emotional instability during childhood or at any period ... severe health disorder, according to recent studies. // ... to become so lethargic that he or she can't ... It affects between 400,000 and 900,000 American adults. , ...
... practice of using duct tape a strong wide adhesive tape ... on skin of hands or feet in schoolchildren. ... popularly attested belief that duct tape is helpful in some ... to popular belief the duct tape only works slightly better ...
... percent rise in the number of tuberculosis cases in ... latest official figures reveal. ,The largest increase ... from 4,696 in 2004 to 5,310 in 2005, figures ... head of the Respiratory Diseases Department at the Agency, ...
Cached Medicine News:Health News:Consequences Of Smoking On Fractures & Ligament Injuries 2Health News:TB Cases On The Rise Among British Asians 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: